Collaborative projects

Olink Bioscience is involved in several collaborative projects that are financed by grant funding bodies. To discuss a collaborative project, please contact us.

Molecular Tools for Research and Diagnostics

Our scientific founders at Uppsala University focus on developing new powerful molecular diagnostic techniques and identifying informative biomarkers. Applications for PLA include PLA on membranes and filters, such as for Western blot (see Liu Y, et al. Western blotting via proximity ligation for high performance protein analysis. Mol Cell Proteomics. 2011 Aug 2), cells in suspension (flow cytometry, see Leuchowius KJ, et a. Flow cytometric in situ proximity ligation analyses of protein interactions and post-translational modification of the epidermal growth factor receptor family. Cytometry A. 2009 Oct;75(10):833-9), and protein-nucleic acid interactions.

For more information please visit: Uppsala University/Molecular Tools for Research and Diagnostics

Vinnova

Olink Bioscience and its affiliated company Halo Genomics is participating in the project “Companion Diagnostics Initiative” which is financed by Vinnova and aims to develop improved cancer diagnostics to increase survival rate of patients with colorectal cancer. The project is coordinated by Professor Mats Nilsson at the Department of Genetics and Pathology and involves several clinical and pre-clinical research groups at Uppsala University.

Vinnova MUX

Olink Bioscience is running an 18-months project “Next generation immunoassays for groundbreaking biomarker research” sponsored by Vinnova. This project aims at developing immunoassay reagents capable of detecting large sets of putative biomarkers for high throughput screening in human blood samples. The immunoassays will be based on Olink’s proprietary Proximity Extension Assay technology (PEA), which besides its excellent specificity and high sensitivity, also possess the ability for high degree of multiplexing required for detailed biomarker studies. More specifically, within the scope of the project Olink Bioscience will develop two different 96-plex panels to measure disease-relevant target proteins, with a product commercialization to follow. This technology platform will thereby represent the to-date highest level of multiplexing for sensitive antibody-based immunoassays.
For more information, please contact Erika Assarsson erika.assarsson@olink.com

READNA

READNA is a four year project running from the 1st of June 2008 until the 31st of May 2012 and is funded by the FP7 framework programme of the European Commission. Within the project Olink will develop its proprietary Selector technology for measuring copy number and methylation pattern variations of clinical relevance using various read out formats.
The project will be co-ordinated by the CEA (France) with partners coming from several European countries including the United Kingdom, France, Germany, Sweden, Denmark and Holland. Apart from the research activities, READNA will also be organising meetings, workshops and will be present at a number of international conferences.
The READNA consortium unites leading researchers from ten academic institutions, three SMEs and three large companies. Participants come from a diverse range of scientific disciplines. The interdisciplinary nature of the consortium will allow the exploration of novel concepts of nucleic acid analysis. Via the READNA project, results are expected to improve many aspects of patient care including the development of new personalised medical strategies and treatments. The combination of academic and industrial partners will encourage the fast and efficient transition from basic research to commercially available technologies.

Project homepage:

http://www.cng.fr/READNA/index.html

DiaTools - Tools for minimally invasive diagnostics

A new generation of molecular tools is becoming available that can digitally record numbers, identities and locations of a broad range of molecular markers for increased diagnostic accuracy. This project will for the first time combine synergistically several groundbreaking technological innovations by the partners, notably padlock and proximity probes with rolling circle amplification for single molecule detection and counting, directed self-assembly of solid phases, and advanced micro-fluidics and read-out techniques, bringing these from the research lab into integrated instruments useful in routine. This will enable minimally invasive diagnostics, prognostics, and follow-up of treatment of cancers. Blood samples and fine needle aspirates will be subjected to high content, multiplex and multimodal assays of nucleic acids, proteins and interacting complexes thereof in single cells as well as in cell-free bodily fluids.
We will use flow cytometry to collect multi-parameter information for large populations of cells, and individual detected molecules will be recorded using a fluorescence activated molecule counter developed by one of the partners. Also, very rare cells and molecules will be targeted through enrichment techniques using novel capturing approaches of unprecedented efficiency. We will apply these diagnostic approaches to characterize biomarkers in solid tumours and in leukemia and lymphoma for minimally invasive diagnostics, monitoring disease progress and selecting optimal therapy, and the assays will be clinically validated in small-scale studies of well-characterized patient samples.